Nuclear hormone receptor was performed by DiscoverX (Fremont, CA) on their NHR-Scan platform of cell-based protein-protein interaction assays. This platform employs a β-gal reporter that activates upon interaction of full-length receptor protein with steroid coactivator receptor peptides. In agonist mode, activity of CL2-57 at 10 µM is compared to maximal activity of published positive control agonists; in antagonist mode, reduction in activity with 10 µM CL2-57 from that observed at EC80 of published agonists is quantified.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.